Know Cancer

or
forgot password

A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of 2 Dosing Schedules Of PF-00299804 In Patients With Advanced Malignant Solid Tumors


Phase 1
18 Years
N/A
Not Enrolling
Both
Neoplasms

Thank you

Trial Information

A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of 2 Dosing Schedules Of PF-00299804 In Patients With Advanced Malignant Solid Tumors


Inclusion Criteria:



- Malignant solid tumor for which there is no currently approved treatment

- Adequate bone marrow, liver, cardiac, and kidney function

Exclusion Criteria:

- Cardiac disease

- Anticancer therapy within 4-6 weeks (depending on therapy)

- Pregnant or breast-feeding

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety

Outcome Time Frame:

6 months

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A7471001

NCT ID:

NCT00225121

Start Date:

October 2005

Completion Date:

September 2010

Related Keywords:

  • Neoplasms
  • Neoplasms

Name

Location

Pfizer Investigational SiteBlendora, California  91740
Pfizer Investigational SiteAurora, Colorado  80012
Pfizer Investigational SiteNorth Adams, Massachusetts  01247